C07C233/24

COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO
20210309620 · 2021-10-07 ·

Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO
20210309620 · 2021-10-07 ·

Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORM

The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative and to novel intermediates of said process.

PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORM

The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative and to novel intermediates of said process.

PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORM

The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative and to novel intermediates of said process.

Process for converting S-enantiomer to its racemic form

The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative.

Process for converting S-enantiomer to its racemic form

The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative.

PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORM

The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative and to novel intermediates of said process.

PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORM

The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative and to novel intermediates of said process.

PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORM

The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative and to novel intermediates of said process.